Jane S. Ricciuti, RPh, MS


August 18, 2004

In This Article


The US Food and Drug Administration (FDA) approved Campral (acamprosate) for the maintenance of abstinence in alcohol-dependent patients by altering the normal balance between neuronal excitation and inhibition.

Botox Cosmetic (botulinum toxin type A) received a supplemental approval for the treatment of primary axillary hyperhidrosis. Botulinum toxin is thought to stop release of acetylcholine, temporarily blocking the nerves in the underarm that stimulate sweating.

This month's column reviews FDA new product approvals and labeling changes for:

Anti-infective Agents

  • Alinia (nitazoxanide) Oral Suspension and Tablets

Dermatologic Agents

  • Botox Cosmetic (Botulinum Toxin Type A)

Nonsteroidal Anti-inflammatory Agents

  • Mobic (meloxicam) Tablets

Oncologic Agents

  • Aldara (imiquimod) Topical Cream

Psychopharmacologic Agents

  • Campral (acamprosate) Tablets


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.